Hepatitis B immune globulin and HBV-related liver transplantation

Expert Opinion on Biological Therapy

Volumn 8, Issue 11, 2008, Pages 1815-1822

  Akay, Sinan ^a   Karasu, Zeki ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

HBV related liver transplantation; Hepatitis B immune globulin

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; BINDING AFFINITY; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MALAISE; MONOTHERAPY; NAUSEA; RECURRENT DISEASE; TREATMENT RESPONSE; VACCINATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

EID: 56249129752     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.11.1815     Document Type: Article

References (58)

1. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832-8
2. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003;39:466-74
3. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003;38:86-95
4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993;329:1842-7
5. National Institutes of Health Consensus Development Conference Statement: Liver Transplantation. Hepatology 1984;(4 Suppl):S107
6. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-5
7. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987;19:4051-3
8. Lok A. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8:S67-73
9. Bihl FK, Gurtner V, Russman S, et al. Hyperimmune anti-HBs plasma for the prevention of HBV recurrence after liver transplan cation: efficacy, safety, kinetics and economics in 26 patients during 14-year experience of two centers. Hepatology 2007;46(4 Suppl 1):472A
10. Shouval D, Terrault NA, Galun E, et al. Anti-viral effects, pharmacokinetics and safety of two human monoclonal anti HBs (Libivirumab/Exbivirumab) versus hepatitis B immune globulin in hepatitis B virus in liver transplant recipients. Hepatology 2006;44 (4 Suppl 1): 196A
11. Pan T, Tang L, Yuan J, et al. Recombinant anti-HBs Ag Fab blocks hepatitis B virus infection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2007;6:370-5
12. Previsani N, Lavanchy D, Zuckerman AJ. Hepatitis B. Viral hepatitis. In: Mushawar IK, editor, Perspectives in medical virology. Volume 10. Amsterdam: Elsevier; 2004. p. 31-98
13. Bowman JM, Friesen AD, Pollock JM, Taylor WE. WinRho: Rh immune globulin prepared by ion exchange for intravenous Use. Can Med Assoc J 1980;123:1121-7
14. Horowitz B. Investigations into the application of tri(n-butyl)phosphate/ detergent mixtures to blood derivatives. Curr Stud Hematol Blood Transfus 1989;56:83-96
15. Burnouf T. Value of virus filtration as 2 method for improving the safety of plasma products. Vox Sang 1996;70:235-6
16. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68
17. Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003;77:8882-92
18. Feray C, Zignego AL, Samuel D, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection: the liver transplantation model. Transplantation 1990;49:1155-8
19. Michalac TI, Lau JY, McFarlane BM, et al. Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B. Clin Exp Immunol 1995;100:227-32
20. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8
21. Adler R, Safadi R, Caraco Y, et al. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999;4:1299-305
22. McGory RW, Ishitani MB, Oliveira WM, et aL Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-64
23. Rosenau J, Kreutz T, Kujawa M, et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 2007;46:635-44
24. Dickson RC, Terrault NA, Ishitani M, et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006;12:124-33
25. Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008;14:435-42
26. Devlin J, Smith HM, O'Grady JG, et al. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994;21:204-10
27. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-33
28. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-22
29. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-8
30. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-9
31. Lee PH, Hu RH, Tsai MK, et al. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 2000;32:2245-7
32. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611-9
33. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-35
34. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10
35. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902
36. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491-6
37. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-5
38. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:512-9
39. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-33
40. Di Paolo D, Tiscone G, Piccolo P, et al. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004;77-1203
41. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004;9:921-7
42. Gane EJ, Angus PW, Strasser S, et al.; Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931-7
43. Karasu Z, Akyildiz M, Kilic M, et al. Living donor liver transplantation for hepatitis B cirrhosis. J Gastroenterol Hepatol 2007;22:2124-9
44. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72:1381-5
45. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-13
46. Akyildiz M, Karasu Z, Zeytunlu M, et al. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B vinis infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007;22:2130-4
47. Schiff E, Lai CL, Hadziyannis S, et al.; Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-60
48. Akay S, Karasu Z, Akyildiz M, Tokat T. Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transplant Proc 2004;36:2768-70
49. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94
50. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-7
51. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000;6:434-9
52. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000;31:496-501
53. Karasu Z, Ozacar T, Akarca U, et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005;12:212-5
54. Bienzle U, Günther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;40:811-9
55. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35:176-81
56. Al-Hemsi B, McGory RW, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996;10:668-75
57. Lowell JA, Burgess S, Shenoy S, et al. Mercury poisoning associated with high dose hepatitis B immune globulin administration after liver transplantation. Liver Transpl Surg 1996;2:475-8
58. Anderson RD, Chinnakotla S, Guo L, et al. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007;21:510-7